MSD to support Transgene and BioInvent led oncolytic virus clinical trial 28-Jun-2022 By Jane Byrne MSD will supply Keytruda (pembrolizumab) in a phase 1/2a clinical trial for the treatment of patients with solid tumors, as part of an agreement with Transgene and BioInvent.